Delisting Announcement • Oct 11, 2024
Delisting Announcement
Open in ViewerOpens in native device viewer
PARIS, France, October 11, 2024, 6:00 p.m. (CEST) - Abivax SA (Euronext Paris & Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients witch chronic inflammatory diseases, today announced that it has ended the liquidity contract signed on February 4, 2019 with TRADITION SECURITIES AND FUTURE (TSAF SA). The termination is effective from September 30, 2024, after the close of Euronext market.
On the termination date of this contract, the following assets appeared on the liquidity account:
As a reminder, for the latest half-year statement as of June 30, 2024, the following assets appeared on the liquidity account:
And between July 1st, 2024, and September 30, 2024, included:
| Buy side | Traded volume : 1,070 shares |
€12,014.60 | 10 transactions |
|---|---|---|---|
| Sell side | Traded volume : 12,501 shares |
€132,638.86 | 26 transactions |
Moreover, the following resources were allocated to the liquidity contract for its implementation beginning June 26th, 2015 (date of the initial contract entered into between the Company and TSAF SA, which was replaced by the above-mentioned contract):
The liquidity account returned €500,000.00 in cash to Abivax on April 15, 2020.
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax' s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX.
Abivax Finance department Didier Blondel [email protected] +33 1 53 83 08 41
Investor Relations France Seitosei ● Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24
Abivax Investor Relations Patrick Malloy [email protected] +1 847 987 4878
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.